Synopsis
Synopsis
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Australia
0
South Africa
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. K2hpo4
2. Kd2po4
3. Potassium Acid Phosphate
4. Potassium Dideuterium Phosphate
5. Potassium Dihydrogen Phosphate
6. Potassium Monohydrogen Phosphate
7. Potassium Phosphate
8. Potassium Phosphate (k-h2po4)
9. Potassium Phosphate (k-h3po4(1:2))
10. Potassium Phosphate (k2-hpo4)
11. Potassium Phosphate (k3-po4)
12. Potassium Phosphate, Dibasic
13. Potassium Phosphate, Monobasic
14. Potassium Phosphate, Unspecified Form
1. 7758-11-4
2. Dipotassium Phosphate
3. Potassium Phosphate Dibasic
4. Dipotassium Hydrogenphosphate
5. Dibasic Potassium Phosphate
6. Potassium Hydrogen Phosphate
7. Potassium Phosphate, Dibasic
8. Phosphoric Acid, Dipotassium Salt
9. Potassium Dibasic Phosphate
10. Dipotassium Monophosphate
11. Potassium Monohydrogen Phosphate
12. K2hpo4
13. Potassium Monophosphate
14. Dipotassium Hydrogenorthophosphate
15. Dipotassium Monohydrogen Phosphate
16. Dipotassium Orthophosphate
17. Mfcd00011383
18. Hydrogen Dipotassium Phosphate
19. Potassium Phosphate (dibasic)
20. Di-potassium Hydrogen Phosphate
21. Dipotassium Hydrogen Orthophosphate
22. Sec.-potassium Phosphate
23. Dipotassium Acid Phosphate
24. Potassium Hydrogenphosphate
25. Phosphoric Acid, Potassium Salt (1:2)
26. Secondary Potassium Phosphate
27. Ci71s98n1z
28. Ins No.340(ii)
29. Ins-340(ii)
30. Dipotassium Hydrogen Monophosphate
31. E-340(ii)
32. Potassium Phosphate Dibasic, Acs Reagent
33. Isolyte
34. Dipotassium-o-phosphate
35. Dipotassium;hydrogen Phosphate
36. Ccris 6544
37. Hsdb 935
38. Kali Phosphoricum
39. Leex-a-phos
40. Einecs 231-834-5
41. Mediject P (tn)
42. Di Potassium Phosphate
43. Potassiumhydrogenphosphate
44. Potassium Phosphate,dibasic
45. Dipotasium Hydrogen Phosphate
46. Unii-ci71s98n1z
47. Potassium Monohydrogenphosphate
48. Potassium Hydrogen Monophosphate
49. Chembl1200459
50. Dtxsid8035506
51. Kali Phosphoricum [hpus]
52. Chebi:32031
53. Chebi:131527
54. Dipotassium Phosphate [inci]
55. Dipotassium Monohydrogen Orthophosphate
56. Potassium Dibasic Phosphate Trihydrate
57. Potassium Phosphate (k2hpo4)
58. Akos015915872
59. Akos016371887
60. Db09414
61. Potassium Hydrogen Phosphate, Anhydrous
62. Potassium Phosphate [green Book]
63. Potassium Phosphate, Dibasic, Anhydrous
64. Potassium Phosphate, Dibasic (jan/usp)
65. Potassium Phosphate, Dibasic [usp:jan]
66. Potassium Phosphate Dibasic, Lr, >=98%
67. Potassium Phosphate, Dibasic [ii]
68. Potassium Phosphate, Dibasic [mi]
69. Sy010082
70. Di-potassium Hydrogen Orthophosphate
71. Dipotassium Phosphate [ep Impurity]
72. Potassium Phosphate, Dibasic [fcc]
73. Potassium Phosphate, Dibasic [jan]
74. Potassium Phosphate,dibasic [vandf]
75. Dipotassium Phosphate [ep Monograph]
76. Potassium Phosphate Dibasic Anhydrate
77. Potassium Phosphate, Dibasic [hsdb]
78. Dibasic Potassium Phosphate [usp-rs]
79. Potassium Phosphate Dibasic [who-dd]
80. Potassium Phosphate Dibasic Solution, 1.0 M
81. Potassium Phosphate Dibasic, Biochemical Grade
82. Potassium Phosphate Dibasic, Puriss., >=99%
83. D02403
84. Dipotassium Hydrogen Phosphate (k2hpo4)
85. Ec 231-834-5
86. Dibasic Potassium Phosphate [usp Impurity]
87. Dibasic Potassium Phosphate [usp Monograph]
88. Potassium Phosphate Dibasic, Acs Reagent, >=98%
89. Potassium Phosphate Dibasic, Usp, 98.0-100.5%
90. Potassium Phosphate, Dibasic [orange Book]
91. Q403721
92. Potassium Phosphate Dibasic, Ar, Anhydrous, >=99%
93. Potassium Phosphate, Dibasic [usp Impurity]
94. Potassium Phosphate Dibasic, Reagent Grade, >=98.0%
95. Potassium Phosphate Dibasic, 99.95% Trace Metals Basis
96. Potassium Phosphate Dibasic, Saj First Grade, >=98.0%
97. Potassium Phosphate Dibasic, Trace Metals Grade 99.95%
98. Potassium Phosphate Dibasic, Jis Special Grade, >=99.0%
99. Potassium Phosphate Dibasic, Vetec(tm) Reagent Grade, 98%
100. Potassium Phosphate Dibasic, Meets Usp Testing Specifications
101. Dibasic Potassium Phosphate Component Of Potassium Phosphates
102. Potassium Phosphates Component Dibasic Potassium Phosphate
103. Dibasic Potassium Phosphate, United States Pharmacopeia (usp) Reference Standard
104. Potassium Phosphate Dibasic, Anhydrous, Free-flowing, Redi-dri(tm), Acs Reagent, >=98%
105. Potassium Phosphate Dibasic, Puriss. P.a., Acs Reagent, Anhydrous, >=99.0% (t)
106. Potassium Phosphate Dibasic Anhydrous, Pharmagrade, Usp, Manufactured Under Appropriate Gmp Controls For Pharma Or Biopharmaceutical Production.
107. Potassium Phosphate Dibasic, Anhydrous, For Luminescence, For Molecular Biology, Bioultra, >=99.0% (t)
Molecular Weight | 174.176 g/mol |
---|---|
Molecular Formula | HK2O4P |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 0 |
Exact Mass | 173.88865848 g/mol |
Monoisotopic Mass | 173.88865848 g/mol |
Topological Polar Surface Area | 83.4 Ų |
Heavy Atom Count | 7 |
Formal Charge | 0 |
Complexity | 46.5 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
CATHARTIC
Budavari, S. (ed.). The Merck Index - Encyclopedia of Chemicals, Drugs and Biologicals. Rahway, NJ: Merck and Co., Inc., 1989., p. 1216
Factors affecting calcium-phosphate solubility in parenteral nutrition solutions used in neonates were studied. Six neonatal parenteral nutrition solutions were prepared using either Aminosyn or FreAmine II and various amino acid and dextrose concentrations. Phosphorus (as mono- and dibasic potassium phosphate) and calcium (as 10% calcium gluconate) were added in concentrations of calcium 2.5-100 meq/l and phosphorus 2.5-100 mmol/l. Duplicate samples were prepared and analyzed either after they were heated in a water bath (37 C) for 20 min or after 18 hr at 25 C followed by 30 min in a water bath (37 C). Precipitation was detected visually and spectrophotometrically, and pH was measured. Lipid emulsion was added to 2 FreAmine II solutions in a ratio of 7.5:1 (parenteral nutrition solution:lipid) and the resulting pH was measured. Time and temperature affected calcium-phosphate solubility in all solutions tested. Precipitation curves of amount of calcium versus amount of phosphate added were prepared for each solution. Amino acid and dextrose concentrations affected the pH of the solutions, and when a lipid emulsion was added, the pH rose more in the 1% than in the 2% FreAmine II solution. In selected solutions, as much as 120 mg/kg/day calcium and 55 mg/kg/day phosphate can be administered, approximating daily third trimester accumulation of these minerals. Use of the precipitation curves in this paper, with attention to their limitations, should aid in the safe delivery of calcium and phosphorus IV to neonates.
PMID:6798868 Eggert LD et al; Am J Hosp Pharm 39 (Jan): 49-53 (1982)
SALINE BULK CATHARTIC
Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 744
Oral administration is safer, but careful monitoring of serum electrolyte levels and renal function is necessary. Nausea, vomiting, and diarrhea may occur and may be dose dependent. Concomitant use of antacids containing aluminum and/or magnesium should be avoided, because they may bind phosphate and prevent it absorption (calcium antacids also may bind phosphate, and it is assumed that these agents are not given to hypercalcemic patients).
American Medical Association, Department of Drugs. Drug Evaluations. 6th ed. Chicago, Ill: American Medical Association, 1986., p. 897
Phosphate should not be given to patients with impaired renal function or hyperphosphatemia. They should not be given to patients with alkaline urine due to urinary tract infections because increased calcium and phosphate concentrations in the alkaline urine increase the risk of calcium phosphate stones.
American Medical Association, Department of Drugs. Drug Evaluations. 6th ed. Chicago, Ill: American Medical Association, 1986., p. 897
Intravenous administration of phosphates is dangerous. Hypocalcemia, hypotension and shock, myocardial infarction, tetany, and acute renal failure have occurred, and deaths have been reported. Deposition of calcium phosphate in the kidney, heart, lung, and blood vessels also may be fatal. For these reasons, intravenous therapy is not justified in the treatment of hypercalcemia. Phosphates should not be administered to patients with impaired renal function or hyperphosphatemia. They also should not be given to patients with alkaline urine due to urinary tract infections because increased calcium and phosphate concentrations in the alkaline urine increase the risk of calcium phosphate stones. Phosphate should be given as the potassium rather than the sodium salt because the latter causes volume expansion and inhibits phosphate reabsorption, thus negating the therapeutic effect. /Phosphate salt/
American Medical Association. AMA Drug Evaluations Annual 1991. Chicago, IL: American Medical Association, 1991., p. 1951
The most common adverse effect of phosphate salts is diarrhea. Patients with kidney stones may pass old stones when phosphate therapy is started and should be warned of this possibility. Phosphates are contraindicated in patients with infected stones and in those with renal function less than 30% of normal. /Orthophosphates/
American Medical Association, Department of Drugs. Drug Evaluations. 6th ed. Chicago, Ill: American Medical Association, 1986., p. 584
Dipotassium phosphate is used in imitation dairy creamers, dry powder beverages, mineral supplements, and starter cultures as an additive. It is used in non-dairy creamers to prevent coagulation. Dipotassium phosphate is also used to make buffer solutions and it is used in the production of trypticase soy agar which is used to make agar plates for culturing bacteria.
Phosphate is a major intracellular anion which participates in providing energy for metabolism of substances and contributes to important metabolic and enzymatic reactions in almost all organs and tissues. Phosphate exerts a modifying influence on calcium concentrations, a buffering effect on acid-base equilibrium, and has a major role in the renal excretion of hydrogen ions.
Cariostatic Agents
Substances that inhibit or arrest DENTAL CARIES formation. (Boucher's Clinical Dental Terminology, 4th ed) (See all compounds classified as Cariostatic Agents.)
Buffers
A chemical system that functions to control the levels of specific ions in solution. When the level of hydrogen ion in solution is controlled the system is called a pH buffer. (See all compounds classified as Buffers.)
Absorption
Potassium salts are well absorbed from gastro intestinal tract. Net phosphorus absorption may occur in the small intestine in some species but is primarily a function of the colon in horses.
Route of Elimination
Potassium is excreted primarily by kidney.
Volume of Distribution
Distribution is largely intracellular, but it is the intravascular concentration that is primarily responsible for toxicity.
Clearance
Phosphates are rapidly cleared by dialysis.
POTASSIUM SALTS ARE WELL ABSORBED FROM THE GASTROINTESTINAL TRACT. ... POTASSIUM IS EXCRETED PRIMARILY BY THE KIDNEY. /POTASSIUM SALTS/
McEvoy, G.K. (ed.). AHFS Drug Information 90. Bethesda, MD: American Society of Hospital Pharmacists, Inc., 1990 (Plus Supplements 1990)., p. 1425
Net phosphorus absorption may occur in the small intestine in some species but is primarily a function of the colon in horses. /SRP: Phosphates/
Booth, N.H., L.E. McDonald (eds.). Veterinary Pharmacology and Therapeutics. 5th ed. Ames, Iowa: Iowa State University Press, 1982., p. 640
/Ortho/ phosphate is absorbed from, and to a limited extent secreted into, the gastrointestinal tract. Transport of phosphate from the gut lumen is an active, energy-dependent process that is modified by several factors. ... Vitamin D stimulates phosphate absorption, an effect reported to precede its action on calcium ion transport. In adults, about two thirds of the ingested phosphate is absorbed, and that which is absorbed is almost entirely excreted into the urine. In growing children, phosphate balance is positive. Concentrations of phosphate in plasma are higher in children than in adults. This "hyperphosphatemia" decreases the affinity of hemoglobin for oxygen and is hypothesized to explain the physiological "anemia" of childhood. /Phosphates/
Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 1524
Phosphate is a major intracellular anion which participates in providing energy for metabolism of substances and contributes to important metabolic and enzymatic reactions in almost all organs and tissues.
In healthy children with phosphate overdose, half-life was 4.8 to 10.6 hours, and was prolonged to 17 hours in a child with renal insufficiency.
Once phosphate gains access to the body fluids and tissues, it exerts little pharmacological effect. If the ion is introduced into the intestine, the absorbed phosphate is rapidly excreted. If large amounts are given by this route, much of it may escape absorption. Because this property leads to a cathartic action, phosphate salts are employed as mild laxatives.
Once phosphate gains access to the body fluids and tissues, it exerts little pharmacological effect. If the ion is introduced into the intestine, the absorbed phosphate is rapidly excreted. If large amounts are given by this route, much of it may escape absorption. Because this property leads to a cathartic action, phosphate salts are employed as mild laxatives. Inorganic phosphate poisoning following ingestion of laxatives that contain phosphate salts has been reported in adults and children. Ingestion of large amounts of sodium dihydrogen phosphate lowers urinary pH. If excessive phosphate salts are introduced intravenously or orally, they may prove toxic by reducing the concentration of Ca 2+ in the circulation and from the precipitation of calcium phosphate in soft tissues. /Phosphates/
Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 1525
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Medichem is a vertically integrated pharmaceutical company specializing in the development & manufacturing of APIs & FDFs.
Regulatory Info :
Registration Country : Spain
Potassium Phosphate; Potassium Dihydrogen Phosphate
Brand Name :
Dosage Form : Intravenous Vial
Dosage Strength : 236MG/ML; 224MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Spain
Regulatory Info : DISCN
Registration Country : USA
AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
Brand Name : AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 4.25%;10GM/100ML;51MG/100ML;176.5MG/100ML;22.4MG/100ML;104.5MG/100ML;205MG/100ML
Packaging :
Approval Date : 1988-09-08
Application Number : 19712
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info : DISCN
Registration Country : USA
DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
Brand Name : ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 5GM/100ML;150MG/100ML;130MG/100ML;280MG/100ML;91MG/100ML
Packaging :
Approval Date : 1993-06-10
Application Number : 19870
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE
Brand Name : DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 5GM/100ML;31MG/100ML;141MG/100ML;20MG/100ML;12MG/100ML;260MG/100ML
Packaging :
Approval Date : 1982-01-01
Application Number : 17484
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
Brand Name : CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 5%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML
Packaging :
Approval Date : 1997-03-26
Application Number : 20678
Regulatory Info : RX
Registration Country : USA
Regulatory Info : Ethical
Registration Country : Canada
Brand Name : CLINIMIX E
Dosage Form : SOLUTION
Dosage Strength : 261MG/100ML
Packaging :
Approval Date :
Application Number : 2498421
Regulatory Info : Ethical
Registration Country : Canada
Regulatory Info : DISCN
Registration Country : USA
POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC
Brand Name : POTASSIUM PHOSPHATES
Dosage Form : SOLUTION;INTRAVENOUS
Dosage Strength : 4.5GM/15ML (300MG/ML);2.65GM/15ML (175MG/ML)
Packaging :
Approval Date : 2019-09-19
Application Number : 212121
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info : DISCN
Registration Country : USA
AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
Brand Name : AMINOSYN 7% W/ ELECTROLYTES
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 7%;102MG/100ML;522MG/100ML;410MG/100ML
Packaging :
Approval Date : 1982-01-01
Application Number : 17789
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info :
Registration Country : South Korea
Calcium chloride monohydrate; Carboxymethylcellulose Sodium; Dipotassium Hydrogen Phosphate; Sorbitol API; Magnesium Chloride; Sodium Chloride; Potassium Chloride
Brand Name : Xerova Solution
Dosage Form : Solution
Dosage Strength : 15MG; 1G; 34MG; 3G; 5MG; 84MG; 120MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : South Korea
Regulatory Info : RX
Registration Country : USA
POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC
Brand Name : POTASSIUM PHOSPHATES
Dosage Form : SOLUTION;INTRAVENOUS
Dosage Strength : 1.18GM/5ML (236MG/ML);1.12GM/5ML (224MG/ML)
Packaging :
Approval Date : 2024-07-11
Application Number : 217726
Regulatory Info : RX
Registration Country : USA
RLD : No
TE Code :
AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
Brand Name : AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 4.25%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML
Approval Date : 1988-09-12
Application Number : 19714
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code : AP
POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC
Brand Name : POTASSIUM PHOSPHATES
Dosage Form : SOLUTION;INTRAVENOUS
Dosage Strength : 3.54GM/15ML (236MG/ML);3.36GM/15ML (224MG/ML)
Approval Date : 2023-10-02
Application Number : 216274
RX/OTC/DISCN : RX
RLD : No
TE Code : AP
RLD : No
TE Code :
DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
Brand Name : ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 5GM/100ML;150MG/100ML;130MG/100ML;280MG/100ML;91MG/100ML
Approval Date : 1982-01-01
Application Number : 18270
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
Brand Name : TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 4.25%;5GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML
Approval Date : 1995-10-23
Application Number : 20147
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : Yes
TE Code :
AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
Brand Name : CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 2.75%;33MG/100ML;5GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML
Approval Date : 1997-03-26
Application Number : 20678
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
Brand Name : CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 2.75%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML
Approval Date : 1997-03-26
Application Number : 20678
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE
Brand Name : CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 5%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML
Approval Date : 1997-03-26
Application Number : 20678
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : No
TE Code :
AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
Brand Name : AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 4.25%;36.8MG/100ML;20GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML
Approval Date : 1988-11-07
Application Number : 19683
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
Brand Name : AMINOSYN 7% W/ ELECTROLYTES
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 7%;102MG/100ML;522MG/100ML;410MG/100ML
Approval Date : 1982-01-01
Application Number : 17789
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code :
AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE
Brand Name : AMINOSYN II 8.5% W/ ELECTROLYTES
Dosage Form : INJECTABLE;INJECTION
Dosage Strength : 8.5%;102MG/100ML;45MG/100ML;522MG/100ML;410MG/100ML
Approval Date : 1986-04-03
Application Number : 19437
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
Regulatory Info :
Registration Country : Italy
Potassium Dihydrogen Phosphate; Dipotassium Hydrogen Phosphate
Brand Name : Potassium Phosphate
Dosage Form :
Dosage Strength : 5 Ampoules 2 Meq/Ml 10 Ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Potassium Dihydrogen Phosphate; Dipotassium Hydrogen Phosphate
Brand Name : Potassium Phosphate
Dosage Form :
Dosage Strength : 1 Ampoule 2 Meq/Ml 30 Ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Sodium Chloride; Potassium Acetate; Dipotassium Hydrogen Phosphate
Brand Name : Re-Hydration Electrolytic Glucose Calcium Gluconate
Dosage Form :
Dosage Strength : 1 Bottle 1,000 Ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Sodium Chloride; Potassium Acetate; Dipotassium Hydrogen Phosphate
Brand Name : Re-Hydration Electrolytic Glucose Calcium Gluconate
Dosage Form :
Dosage Strength : 1 Bottle 250 Ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Sodium Chloride; Potassium Acetate; Dipotassium Hydrogen Phosphate
Brand Name : Re-Hydration Electrolytic Glucose Calcium Gluconate
Dosage Form :
Dosage Strength : 1 Bottle 100 Ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Sodium Chloride; Potassium Chloride; Dipotassium Hydrogen Phosphate; Sodium Acetate
Brand Name : Maintaining The Electrolytic With Glucose
Dosage Form :
Dosage Strength : 1 Bottle 1,000 Ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Sodium Chloride; Potassium Chloride; Dipotassium Hydrogen Phosphate; Sodium Acetate
Brand Name : Maintaining The Electrolytic With Glucose
Dosage Form :
Dosage Strength : 1 Bottle 1,000 Ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Sodium Chloride; Potassium Chloride; Dipotassium Hydrogen Phosphate; Sodium Acetate
Brand Name : Maintaining The Electrolytic With Glucose
Dosage Form :
Dosage Strength : 1 500 Ml Bottle
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Sodium Chloride; Potassium Chloride; Dipotassium Hydrogen Phosphate; Sodium Acetate
Brand Name : Maintaining The Electrolytic With Glucose
Dosage Form :
Dosage Strength : 1 Bottle 500 Ml 5%
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Sodium Chloride; Potassium Chloride; Dipotassium Hydrogen Phosphate; Sodium Acetate
Brand Name : Maintaining The Electrolytic With Glucose
Dosage Form :
Dosage Strength : 1 Bottle 250 Ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info : OTC
Registration Country : Canada
Brand Name : AVL ELECTROLYTE POWDER
Dosage Form : POWDER FOR SOLUTION
Dosage Strength : 0.349G/76G
Packaging : 76G/1KG/2KG/4KG
Approval Date :
Application Number : 2384248
Regulatory Info : OTC
Registration Country : Canada
Regulatory Info : Ethical
Registration Country : Canada
Brand Name : CLINIMIX E
Dosage Form : SOLUTION
Dosage Strength : 261MG/100ML
Packaging : 2000ML
Approval Date :
Application Number : 2142384
Regulatory Info : Ethical
Registration Country : Canada
Regulatory Info : Ethical
Registration Country : Canada
Brand Name : CLINIMIX E
Dosage Form : SOLUTION
Dosage Strength : 261MG/100ML
Packaging : 1000ML
Approval Date :
Application Number : 2013967
Regulatory Info : Ethical
Registration Country : Canada
Regulatory Info : Ethical
Registration Country : Canada
Brand Name : CLINIMIX E
Dosage Form : SOLUTION
Dosage Strength : 261MG/100ML
Packaging : 1000ML
Approval Date :
Application Number : 2014076
Regulatory Info : Ethical
Registration Country : Canada
Regulatory Info : Ethical
Registration Country : Canada
Brand Name : CLINIMIX E
Dosage Form : SOLUTION
Dosage Strength : 261MG/100ML
Packaging :
Approval Date :
Application Number : 2498413
Regulatory Info : Ethical
Registration Country : Canada
Regulatory Info : Ethical
Registration Country : Canada
Brand Name : CLINIMIX E
Dosage Form : SOLUTION
Dosage Strength : 261MG/100ML
Packaging :
Approval Date :
Application Number : 2498421
Regulatory Info : Ethical
Registration Country : Canada
Regulatory Info : Ethical
Registration Country : Canada
Brand Name : POTASSIUM PHOSPHATES INJECTION, USP
Dosage Form : SOLUTION
Dosage Strength : 236MG/ML
Packaging : 15ML/50ML
Approval Date :
Application Number : 2139545
Regulatory Info : Ethical
Registration Country : Canada
Regulatory Info : Ethical
Registration Country : Canada
Brand Name : POTASSIUM PHOSPHATES
Dosage Form : LIQUID
Dosage Strength : 236MG/ML
Packaging : 10X10ML, 10X50ML
Approval Date :
Application Number : 804789
Regulatory Info : Ethical
Registration Country : Canada
Regulatory Info : OTC
Registration Country : Canada
Brand Name : V-LYTES HE (WATER SOLUBLE NUTRIENT, ELECTROLYTE POWDER FOR ORAL USE IN CALVES)
Dosage Form : POWDER FOR SOLUTION
Dosage Strength : 1.742G/184G
Packaging : 10X18.4G/3.7KG
Approval Date :
Application Number : 1957341
Regulatory Info : OTC
Registration Country : Canada
Regulatory Info : OTC
Registration Country : Canada
Brand Name : CALF-LYTE II
Dosage Form : POWDER FOR SOLUTION
Dosage Strength : 0.349G/76G
Packaging : 24X76/2/4/10KG
Approval Date :
Application Number : 2242113
Regulatory Info : OTC
Registration Country : Canada
Medichem is a vertically integrated pharmaceutical company specializing in the development & manufacturing of APIs & FDFs.
Regulatory Info :
Registration Country : Spain
Potassium Phosphate; Potassium Dihydrogen Phosphate
Brand Name :
Dosage Form : Intravenous Vial
Dosage Strength : 236MG/ML; 224MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Spain
Medichem is a vertically integrated pharmaceutical company specializing in the development & manufacturing of APIs & FDFs.
Packaging :
Regulatory Info :
Potassium Phosphate; Potassium Dihydrogen Phosphate
Dosage : Intravenous Vial
Dosage Strength : 236MG/ML; 224MG/ML
Brand Name :
Approval Date :
Application Number :
Registration Country : Spain
Regulatory Info :
Registration Country : South Korea
Calcium chloride monohydrate; Carboxymethylcellulose Sodium; Dipotassium Hydrogen Phosphate; Sorbitol API; Magnesium Chloride; Sodium Chloride; Potassium Chloride
Brand Name : Xerova Solution
Dosage Form : Solution
Dosage Strength : 15MG; 1G; 34MG; 3G; 5M...
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : South Korea
Packaging :
Regulatory Info :
Calcium chloride monohydrate; Carboxymethylcellulose Sodium; Dipotassium Hydrogen Phosphate; Sorbitol API; Magnesium Chloride; Sodium Chloride; Potassium Chloride
Dosage : Solution
Dosage Strength : 15MG; 1G; 34MG; 3G; 5M...
Brand Name : Xerova Solution
Approval Date :
Application Number :
Registration Country : South Korea
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Dosage Form : Gel
Grade : Parenteral, Oral, Topical
Dosage Form : Injectable / Parenteral
Grade : Parenteral
Brand Name : Lactose Monohydrate
Application : Parenteral
Excipient Details : Lactose monohydrate is used as a diluent in inhalation and lyophilized preparations.
Dosage Form : Gel
Grade : Oral, Topical
Dosage Form : Injectable / Parenteral
Grade : Parenteral, Topical, Oral
Dosage Form : Injectable / Parenteral
Grade : Parenteral, Topical, Oral
Dosage Form : Emulsion
Grade : Topical
Dosage Form : Softgels
Grade : Oral
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?